Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence risk insights to guide more precise, risk-aligned clinical management

FRIENDSWOOD, Texas, April 21, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it will present new data on its DecisionDx-Melanoma test addressing a critical clinical challenge in melanoma care: identifying which patients with early-stage disease are at risk for poor outcomes and may benefit from intensified management. The data will be presented at the 22nd European Congress of Dermato-Oncology (EADO) Congress and the American College of Mohs Surgery (ACMS) 58th Annual Meeting. 

The data to be presented at both meetings further demonstrate that DecisionDx-Melanoma provides clinically actionable, personalized information that refines risk assessment across patients with cutaneous melanoma (CM). Notably, the data show the test can identify patients with thin tumors and early-stage disease whose outcomes may be more consistent with higher-risk melanoma and whose recurrence and survival risk may be underestimated by American Joint Committee on Cancer (AJCC) staging alone, enabling more precise, risk-aligned clinical management.